Field of Science

The Higgs boson and the future of science

My latest post on the Scientific American blog network ties together several threads about reductionism, emergence and the nature of scientific problems which I have explored on this blog.


Philip Anderson: Anderson first described the so-called Higgs mechanism and also fired the first modern salvo against strong reductionism (Image: Celeblist)
The discovery of the Higgs boson (or the "Higgs-like particle" if you prefer) is without a doubt one of the signal scientific achievements of our time. It illustrates what sheer thought - aided by data of course - can reveal about the workings of the universe and it continues a trend that lists Descartes, Hume, Galileo and Newton among its illustrious forebears. From sliding objects down an incline to smashing atoms at almost the speed of light in a 27 kilometer tunnel, we have come a long way. Dissecting our origins and the universe around us scarcely gets any better than this.

Yet even as the exciting discovery was being announced, I could not help but think about what the Higgs does not do for us. It does not speed up the time needed to discover a new cancer drug. It does not help us understand consciousness. It does not tell us how life began or whether it exists elsewhere in the universe. It does not explain romantic love, how to design the best solar cell, why people have certain political preferences and how exactly to predict the effects of climate change. In fact we can safely predict that the discovery of the Higgs boson, as consciousness-elevating as it is, does not impact the daily work of 99% of all pure and applied scientists in the world.

I do not say all this to downplay the discovery of the particle which is an unparalleled triumph of human thought, hard work and experimental ingenuity. I also do not say this to make the obvious point that a discovery in one field of science does not automatically solve problems in other fields. Rather, I say this to probe the deeper reality beyond that point, to highlight the multifaceted nature of science and the sheer diversity of problems and phenomena that it presents to us at every level of inquiry. And I say this with a suspicion that the Higgs boson may be the most fitting tribute to the limitations of what has been the most potent philosophical instrument of scientific discovery - reductionism.

In one sense the discovery of this fundamental component of matter can be seen as the culmination of reductionist thinking, accounting as it does for the very existence of mass. Reductionism is the great legacy of the twentieth century, a philosophy whose seeds were sown when Greek philosophers started mulling the nature of matter. The method is in fact quite intuitive; ever since they stepped down from the trees, human beings have tried to solve problems by breaking them down into simpler parts. In the twentieth century the fruits of reductionism have been nothing short of awe-inspiring. Reductionism is what told us that molecules are made of atoms, that the universe is expanding, that DNA is a double helix and that you can build lasers and computers. The reductionist ethic has given us quantum mechanics, relativity, quantum chemistry and molecular biology. Over the centuries it has been used by its countless practitioners as a fine scalpel which has laid bare the secrets of nature. In fact many of the questions answered using the reductionist method were construed as being amenable to this method even before their answers were provided; for instance, how do atoms combine to form molecules? What is the basic nature of the gene? What are atoms themselves made up of?

Yet as we enter the second decade of the twenty-first century, it is clear that reductionism as a principal weapon in our arsenal of discovery tools is no longer sufficient. Consider some of the most important questions facing modern science, almost all of which deal with complex, multifactorial systems. How did life on earth begin? How does biological matter evolve consciousness? What are dark matter and dark energy? How do societies cooperate to solve their most pressing problems? What are the properties of the global climate system? It is interesting to note at least one common feature among many of these problems; they result from the buildup rather than the breakdown of their operational entities. Their signature is collective emergence, the creation of attributes which are greater than the sum of their constituent parts. Whatever consciousness is for instance, it is definitely a result of neurons acting together in ways that are not obvious from their individual structures. Similarly, the origin of life can be traced back to molecular entities undergoing self-assembly and then replication and metabolism, a process that supersedes the chemical behavior of the isolated components. The puzzle of dark matter and dark energy also have as their salient feature the behavior of matter at large length and time scales. Studying cooperation in societies essentially involves studying group dynamics and evolutionary conflict. The key processes that operate in the existence of all these problems seem to almost intuitively involve the opposite of reduction; they all result from the agglomeration of molecules, matter, cells, bodies and human beings across a hierarchy of unique levels. In addition, and this is key, they involve the manifestation of unique principles emerging at every level that cannot be merely reduced to those at the underlying level.
The traditional picture of science asserts that X can be reduced to Y. Reality is more complicated (Image: P. W. Anderson, Science, 1972)
A classic example of emergence: The exact shape of a termite mound is not reducible to the actions of individual termites (Image: Wikipedia Commons)
























This kind of emergence has long since been seen as key to the continued unraveling of scientific mysteries. While emergence had been implicitly appreciated by scientists for a long time, its modern salvo was undoubtedly a 1972 paper in Science by the Nobel Prize winning physicist Philip Anderson titled "More is Different", a title that has turned into a kind of clarion call for emergence enthusiasts. In his paper Anderson (who incidentally first came up with the so-called Higgs mechanism) argued that emergence was nothing exotic; for instance, a lump of salt has properties very different from those of its highly reactive components sodium and chlorine. A lump of gold evidences properties like color that don't exist at the level of individual atoms. Anderson also appealed to the process of broken symmetry, invoked in all kinds of fundamental events - including the existence of the Higgs boson - as being instrumental for emergence. Since then, emergent phenomena have been invoked in hundreds of diverse cases, ranging from the construction of termite hills to the flight of birds. The development of chaos theory beginning in the 60s further illustrated how very simple systems could give rise to very complicated and counterintuitive patterns and behavior that are not obvious from the identities of the individual components.

Many scientists and philosophers have contributed to considered critiques of reductionism and an appreciation of emergence since Anderson wrote his paper. These thinkers make the point that not only does reductionism fail in practice (because of the sheer complexity of the systems it purports to explain), but it also fails in principle on a deeper level. In his book "The Fabric of Reality" for instance, the Oxford physicist David Deutsch has made the compelling point that reductionism can never explain purpose; to drive home this point he asks us if it can account for the existence of a particular atom of copper on the tip of the nose of a statue of Winston Churchill in London. Deutsch's answer is a clear no, since the fate of that atom was based on contingent, emergent phenomena, including war, leadership and adulation. Nothing about the structure of copper atoms allows us to directly predict that a particular atom will someday end up on the tip of that nose. Chance plays an outsized role in these developments and reductionism offers us little solace to understand such historical accidents.
Complexity theorist Stuart Kauffman who has written about the role of contingency as a powerful argument against strong reductionism (Image: Wikipedia Commons)

An even more forceful proponent of this contingency-based critique of reductionism is the complexity theorist Stuart Kauffman (supposedly an inspiration for the Jeff Goldblum character in "Jurassic Park") who has laid out his thoughts in two books. Just like Anderson, Kauffman does not deny the great value of reductionism in illuminating our world, but he also points out the factors that greatly limit its application. One of his favorite examples is the role of contingency in evolution and the object of his attention is the mammalian heart. Kauffman makes the case that no amount of reductionist analysis could explain tell you that the main function of the heart is to pump blood. Even in the unlikely case that you could predict the structure of hearts and the bodies that house them starting from the Higgs boson, such a deductive process could never tell you that of all the possible functions of the heart, the most important one is to pump blood. This is because the blood-pumping action of the heart is as much a result of historical contingency and the countless chance events that led to the evolution of the biosphere as it is of its bottom-up construction from atoms, molecules, cells and tissues. As another example, consider the alpha amino acids which make up all proteins on earth. These amino acids come in two potential varieties, left-handed and right-handed. With very few exceptions, all the functional amino acids that we know of are left handed, but there's no reason to think that right handed amino acids wouldn't have served life equally well. The question then is, why left-handed amino acids? Again, reductionism is silent on this question mainly because the original use of left-handed amino acids during the origin of life was to the best of our knowledge a matter of contingency. Now some form of reductionism may still explain the subsequent propagation of left-handed amino acids and their dominance in biological processes by resorting to molecular level arguments regarding chemical bonding and energetics, but this description will still leave the origins issue unresolved. Even something as fundamental as the structure and function of DNA - which by all accounts was a triumph of reductionism - is much better explained by principles of chemistry like electrostatic attraction and hydrogen bonding.

Life as we know it is based on left-handed amino acids. But there is no reason why right-handed amino acids could not sustain life (Image: Islamickorner)
Reductionism then falls woefully short when trying to explain two things; origins and purpose. And one can see that if it has problems even when dealing with left-handed amino acids and human hearts, it would be in much more dire straits when attempting to account for say kin selection or geopolitical conflict. The fact is that each of these phenomena are better explained by fundamental principles operating at their own levels. Chemistry has its covalent bonds and steric effects, geology has its weathering and tectonic shifts, neurology has its memory potentiation and plasticity and sociology has its conflict theory. And as far as we can tell, these sciences will continue to progress without needing the help of Higgs bosons and neutrinos. This also seems to make it unlikely that the discovery of a single elegant equation linking the four fundamental forces (the purported "theory of everything"), while undoubtedly representing one of the greatest intellectual achievements of humanity, will give sociologists and economists little pause for thought, even as they continue to study the stock market and democracies using their own special toolkit of bedrock principles.

This rather gloomy view of reductionism may sound like science is at a dead end or at the very least has started collapsing under the weight of its own success. But such a view would be as misplaced as announcements about the "end of science" which have surfaced every couple of years for the last two hundred years. Every time the end of science has been announced, science itself proved that claims of its demise were vastly exaggerated. Firstly, reductionism will always be alive and kicking since the general approach of studying anything by breaking it down into its constituents will continue to be enormously fruitful. But more importantly, it's not so much the end of reductionism as the beginning of a more general paradigm that combines reductionism with new ways of thinking. The limitations of reductionism should be seen as a cause not for despair but for celebration since it means that we are now entering new, uncharted territory. There are still an untold number of deep mysteries that science has to solve, ranging from dark energy, consciousness and the origin of life to more supposedly pedestrian concerns like superconductivity, cancer drug discovery and the behavior of glasses. Many of these questions require interdisciplinary approaches which result in the crafting of fundamental principles that are unique to the problem statement. Such a meld will inherently involve reductionism only as one component.

Now there are some who may not consider these problems as "fundamental" enough but that is because they would be peering through the lens of traditional twentieth century science. One of the sad casualties of the reductionist undertaking is a small group of people who think that cosmology and particle physics constitute the only things truly worth doing and the epitome of fundamental science; the rest is all detail that can be filled in by second-rate minds. This is in spite of the inconvenient fact that perhaps 80% of physicists are not concerned at all with fundamental questions. But you would be deluding yourself if you are thinking that turbulence in fluids is a second-rate problem (still unsolved) for second-rate minds, especially if you remember that Heisenberg thought that God would will be able to provide an explanation for quantum mechanics but not for turbulence. The fact is that "pedestrian" concerns like superconductivity have engaged some of the best minds of the last fifty years without fully succumbing to them, and at their own levels they are as hard as the discovery of the Higgs boson or the accelerating universe. Exploring these worthy conundrums is every bit as exciting, deep and satisfying as any other endeavor in science. Those who are wondering what's next should not worry; a sparkling journey lies ahead.

To guide us on this journey all we have to remember are the words of one of the twentieth century's great reductionists and one of Peter Higgs's heroes. Paul Dirac closed his famous text on quantum theory with stirrings that will hopefully be as great a portent for the emergent twenty-first century as they were for the reductionist twentieth: "Some new principles are here needed".

References:
1. P. W. Anderson, More is Different, Science, 1972, 177, 393
2. David Deutsch, "The Fabric of Reality", 2004
3. Stuart Kauffman, "Reinventing the Sacred", 2009; "At Home in the Universe", 1996
Other reading:
1. Terrence Deacon, "Incomplete Nature", 2011
2. John Horgan, "The End of Science", 1997
3. Robert Laughlin, "A Different Universe", 2006

Change is here

As they say, the essence of chemistry is change, so it seems only fitting that I will be moving part of my blogging to a new blog (with the same name) on the Scientific American blogging network. My first post talks about what gets me out of bed every morning (it's not breakfast). Many thanks to Bora Zivkovic for this great opportunity. At SciAm I will be joining a first-rate cast of writers who between them seem to have every field of human inquiry covered.

Am I leaving FoS then? Far from it. FoS has introduced me to some great bloggers and has also provided me with a fine platform. The way I intend to do this is to save the more technical and drug discovery related posts for this site while holding forth on other topics on SciAm. That should ensure that both sites have something different to offer. I will of course be linking to posts on the other site; you could comment on those posts either there or here.

As always, what makes a blog successful are the readers and commentators. Through Twitter, Facebook and mentions on other blogs, many of my posts have gotten more attention than they deserved and for that I am thankful; you should believe me when I say that I have learnt much more from you than you could ever learn from my posts. Hopefully you will continue to hang around both this site and the other one, and I hope to continue benefiting from the interactions.

Zn(III)? Not so fast

Chemists love rogues, oddballs which seem to defy the rules and bond, react, and exist on their own terms. The rogues are valuable because they push the boundaries, teach us about new principles of structure and reactivity and challenge coveted preconceptions. One of the most striking rogues in the history of chemistry was the compound xenon hexafluoroplatinate which shattered belief in the non-reactivity of noble gases. Another immensely productive rogue was the first stable carbocation, a species that was considered too unstable to isolate until George Olah surmounted the energy barrier. Some rogues are literal rogues in the sense that they need to be incarcerated in order to prevent their unruly bonds from going haywire; witness the classic taming of cyclobutadiene by Donald Cram. There's no doubt about it; rogues' galleries are shining gems in the chemical establishment.

A couple of months ago it seemed that another minor rogue had made its appearance. Students around the world know that the most stable oxidation state of zinc is +2. The rationale is simple; unlike transition metals like iron and nickel, zinc contains a fully filled d orbital with an electronic configuration of d10s2. It is therefore quite happy to lose its outermost 2s electrons and remain stable. Thus it came as a surprise when a paper detailing theoretical calculations on zinc compounds predicted the existence of a complex with Zn as Zn(III). That fact would have raised the eyebrows of a million freshmen memorizing transition metals trends for their final exams. The existence of the unusual zinc was based on quantum chemical calculations done by Puru Jena's group at VCU and their basic rationale was that a ligand that was oxidizing and electronegative enough would essentially force the metal to donate extra electrons. They seemed to find such a complex in Zn(AuF6)3. On the face of it that would make sense, but it's worth keeping in mind that nature loves filled orbitals; for instance, even a ligand as oxidizing and electronegative as CF3 does not force copper to adopt the +2 state (copper's most stable oxidation state being +1, resulting from its d10s1 configuration).

Now another paper suggests, with ample evidence it seems, that the suspected Zn(III) rogue might be an upstanding chemical citizen after all. Sebastian Riedel's group in Berlin has examined the purported Zn(III) complex and found that not only does zinc adopt its good old +2 oxidation state in the compound, but that the compound would not be thermodynamically stable. They use a quantum chemical method more sophisticated than the previous one and include more relativistic effects. Where does relativity enter the picture, you ask. It turns out that for heavy metals, the speed (in a crude sense) of the d s-electrons can be fast enough to warrant relativistic calculations; indeed, relativistic quantum chemistry has shed light on many commonplace and yet unusual phenomena, like the color of gold and the liquid state of mercury at room temperature. Relativity is not the exclusive domain of physicists.

I am not enough of an expert in quantum chemistry, but it clearly seems from the latest paper that the more accurate calculations which account for finer details of electron correlation and relativistic effects indicate something striking; the purported complex with Zn in the +3 oxidation state would undergo an exothermic reaction. Put simply, it would not be stable and would decompose to a compound with good old Zn(II). For me, a more troubling fact was the structure of the compound published in the original paper. The structure was supposed to be a low-energy minimum but it has two fluorines practically colliding with each other in an unholy, 197 pm, sub-Van der Waals radius squeeze (illustrated above). The present calculations find another low-energy structure existing only 10 kJ/mol above the previous structure that is consistent with a Zn(II) state. Other calculations indicate that the fluorines in the previously proposed structure are best described as radical anions bridging two AuF5 units.

There's other theoretical evidence in there too, along with citations of experimental facts that point to the recalcitrance of Zn to adopt a +3 state. The study seems to be as solid a piece of evidence against Zn(III) as can be obtained using current levels of theory. But the real reason I want to point out this paper is because it illustrates one of the key roles of theory and computation in chemistry; as an invitation to experiment. Just because the complex is thermodynamically unstable does not mean it cannot be isolated under any conditions. One of the great lessons of chemical science in the last forty years has been the fact that given the right conditions almost anything can be synthesized, stored and isolated (Cram's cyclobutadiene again being a case in point) and that the words stable and unstable are highly relative constructions created by an impoverished chemical lexicon.

This tussle between two predictions illustrates the function of theory in chemistry as the ultimate teaser; if I were an experimentalist I would be rubbing my hands in glee, sending my armies of postdocs and graduate students into the lab to try to synthesize Zn(AuF6)3. As Excimer commented on another site, "Enough theory! Someone make the damn thing already".
Image source: ACS publications.


"Arsenic bacteria": Coffin, meet nails

For those dogged souls still following the whole debacle of arsenic-eating bacteria, it seems that Science has published what should be close to the death knell for "arsenic life". I already mentioned the report by Rosy Redfield and there's another one by Tobias Erb's group at ETH. The title of the paper is "GFAJ-1 is an arsenate-resistant, phosphate-dependent organism".

It's worth reflecting on that title again; "arsenate-resistant, phosphate-dependent". Yes, that description applies to GFAJ-1. It also applies to me, Shamu the killer whale, E. coli 0157 and Francis Bacon. In fact it applies to all the normal life forms that we know. So basically the title says that GFAJ-1 is not much different in this respect from any other bacterium that you may happen to find in a thimbleful of mud scooped up from your backyard.

The paper goes on to analyze the behavior of the bacterium in the presence and absence of phosphorus and arsenate. The bacterium seems to survive in tiny concentrations of phosphate, a concentration that was interestingly deemed as an "impurity" in the original Wolfe-Simon studies. It also does not survive on arsenate but starts dividing as soon as trace amounts of phosphorus are added. The authors' conclusion is clear: "We conclude that cultures in the previous study might have grown on trace amounts of phosphate rather than arsenate". This is what several experts had suspected since the beginning. Their suspicion was based on life's extraordinarily resilience and its ability to zealously guard and use every single atom of precious growth nutrients.

The authors also analyze the composition of the biomolecules (nucleotides, sugars etc.) in GFAJ-1 in the presence and absence of arsenate. They find only phosphate incorporated in the organism's essential machinery. While this does not necessarily argue against the use of arsenate, it demonstrates that when given a choice GFAJ-1 clearly prefers phosphate.

That observation is however not as striking as the next one where they find some metabolites containing arsenate, specifically sugars with arsenate appended to them. The question then is, are these metabolites formed biogenically or abiotically? To try to distinguish between these possibilities, the authors ran mock experiments where they treated glucose medium with arsenates. The purported metabolites showed up in the products and their formation is also supported by simple thermodynamic arguments which favor the attachment of arsenates to sugars. Thus it seems that simple chemistry rather than complex biology is sufficient for explaining the small amounts of arsenated metabolites. The scientists further resort to careful experiments to rule out the existence of other arsenated biomolecules.

The sum total of these experiments says that GFAJ-1 can grow in the presence of phosphate, that it cannot grown in arsenate, and that it can grow in high concentrations of arsenate only when supplemented with limiting concentrations of phosphate. Taken together with the other paper by Rosy Redfield, this is as good a case against arsenic-based life that we can make right now.

The papers are good examples of the conservative yet decisive style that scientists are accustomed to pitching their results in. Unfortunately the original authors have not reacted as conservatively. If anything their responses are transparently shallow and unconvincing. When asked about the results, Felisa-Wolfe Simon said that:
"There is nothing in the data of these new papers that contradicts our published data."
That reply almost convinces me that denial is the most sincere form of self-deception.
A current collaborator of Wolfe-Simon had even more remarkable things to say:

“There are many reasons not to find things — I don’t find my keys some mornings,” he said. “That doesn’t mean they don’t exist. The absence of a finding is not definitive.”

To which I might add that there is a possibility that disgruntled unicorns with chemistry PhDs looking for jobs may well exist, since we haven't found any yet.


Update: Paul@Chembark nicely weighs in.

The Uncertainty Principle for climate (and chemical) models

A recent issue of Nature had an interesting article on what seems to be a wholly paradoxical feature of models used in climate science; as the models are becoming increasingly realistic, they are also becoming less accurate and predictive because of growing uncertainties. I can only imagine this to be an excruciatingly painful fact for climate modelers who seem to be facing the equivalent of the Heisenberg uncertainty principle for their field. It's an especially worrisome time to deal with such issues since the modelers need to include their predictions in the next IPCC report on climate change which is due to be published next year.

A closer look at the models reveals that this behavior is not as paradoxical as it sounds, although it's still not clear how you would get around it. The article especially struck a chord with me I see similar problems bedeviling models used in chemical and biological research. In case of climate change, the fact is that earlier models were crude and did not account for many fine-grained factors that are now being included (such as the rate at which ice falls through clouds). In principle and even in practice there's a bewildering number of such factors (partly exemplified by the picture on top). Fortuitously, the crudeness of the models also prevented the uncertainties associated with these factors from being included in the modeling. The uncertainty remained hidden. Now that more real-world factors are being included, the uncertainties endemic in these factors reveal themselves and get tacked on to the models. You thus face an ironic tradeoff; as your models strive to mirror the real world better, they also become more uncertain. It's like swimming in quicksand; the harder you try to get out of it, the deeper you get sucked in.

This dilemma is not unheard of in the world of computational chemistry and biology. A lot of the models we currently use for predicting protein-drug interactions for instance are remarkably simple and yet accurate enough to be useful. Several reasons account for this unexpected accuracy; among them cancellation of errors (the Fermi principle), similarities of training sets to test sets and sometimes just plain luck. Error analysis is unfortunately not a priority in most of these studies, since the whole point is to publish correct results. Unless this culture changes our road to accurate prediction will be painfully slow.

But here's an example of how "more can be worse". For the last few weeks I have been using a very simple model to try to predict the diffusion of druglike molecules through cell membranes. This is an important problem in drug development since even your most stellar test-tube candidate will be worthless until it makes its way into cells. Cell membranes are hydrophobic while the water surrounding them is hydrophilic. The ease with which a potential drug transfers from the surrounding water into the membrane depends among other factors on its solvation energy, on how readily the drug can shed water molecules; the smaller the solvation energy, the easier it is for drugs to get across. This simple model which calculates the solvation energy seems to do unusually well in predicting the diffusion of drugs across real cell membranes, a process that's much more complex than just solvation-desolvation. 

One of the fundamental assumptions in the model is that the molecule exists in just one conformation in both water and the membrane. This assumption is fundamentally false since in reality, molecules are highly flexible creatures that interconvert between several conformations both in water and inside the membrane. To overcome this assumption, a recent paper explicitly calculated the conformations of the molecule in water and included this factor in the diffusion predictions. This was certainly more realistic. To their surprise, the authors found that making the calculation more realistic made the predictions worse. While the exact mix of factors responsible for this failure can be complicated to tease apart, what's likely happening is that the more realistic factors also bring more noise and uncertainty with them. This uncertainty piles up, errors which were likely canceling before no longer cancel, and the whole prediction becomes fuzzier and less useful.

I believe that this is what is partly happening in climate models. Including more real-life factors in the models does not mean that all those factors are well-understood. You are inevitably introducing some known unknowns. Ill-understood factors will introduce more uncertainty. Well-understood factors will introduce less uncertainty. Ultimately the accuracy of the models will depend on the interplay between these two kinds of factors, and currently it seems that the rate of inclusion of new factors is higher than the rate at which those factors can be accurately calculated.

The article goes on to note that in spite of this growing uncertainty the basic predictions of climate models are broadly consistent. However it also acknowledges the difficulty in explaining the growing uncertainty to a public which has become more skeptical of climate change since 2007 (when the last IPCC report was published). As a chemical modeler I can sympathize with the climate modelers. 

But the lesson to take away from this dilemma is that crude models sometimes work better than more realistic ones. Perhaps the climate modelers should remember George Box's quote that "all models are wrong, but some are useful". It is a worthy endeavor to try to make models more realistic, but it is even more important to make them useful.
Image source

Anticancer drugs form colloidal aggregates and lose activity

Over the last few years, one of the most interesting findings in drug screening and testing at a preclinical level has been the observation that many drugs form colloidal aggregates under standard testing conditions and nonspecifically inhibit target proteins which they otherwise would not affect. This are large aggregates, a hundred nanometers or more in diameter, and they cause proteins to stick and partially unfold, creating the illusion of inhibition. This leads to false positives, especially in high-throughput screening protocols. And these false positives can be absolutely rampant.

What's striking is the sheer ubiquity of this phenomenon which has been observed with all kinds of drugs under all kinds of conditions; while the initial observation was limited to isolated protein-based assays, the phenomenon has also been seen in simulated gastric fluids and in the presence of many different kinds of proteins like serum albumin which are found inside the body. The colloid spirit seems to emphatically favor a shotgun approach.

Now a team led by the brother-sister duo Brian and Molly Shoichet (UCSF and Toronto) has found something that should give drug testers further pause for thought; they see some bestselling anticancer drugs forming colloids (shown above) in cell-based assays to an extent that actually diminishes their activity, leading not to false positives but to false negatives. They test seven known anticancer drugs in cell assays both under known colloid forming conditions along with conditions that break the colloids up. This is not as easy as it sounds since it involves adding a detergent which would usually be too toxic to cells; fortunately in this case they find the right one. Another interesting finding is the re-evaluation of a popular dye used to study "leaky" cancer blood vessels; unlike the previously proposed mechanism, the current study seems to suggest that the dye too forms large aggregates and nonspecifically inhibits the protein serum albumin.

The testing essentially reveals that the drugs when they form colloids basically show activity that's so low as to be negligible and equivalent to the controls. That's a self-(un)proclaimed false negative. Now anybody who deals with error analysis knows that false negatives are fundamentally worse than false positives since by definition they cannot even be detected. The present study raises the pertinent question; how many promising drugs might we be missing because they form aggregates and lower the observed response in cells? And since the colloid forming phenomenon has been shown to be so ubiquitous, could it possibly be influencing the mechanism of action of all kinds of drugs inside the body? And in what ways? It's a fascinating question, and one of those that continues to make basic research in drug discovery still so interesting.
Image source and credit: ACS

P-glycoprotein: The vacuum cleaner that makes Sir James weep

There has been a lot of discussion during the last decade about the continuing attrition in the pharmaceutical industry and the absence of novel drugs. Several factors including layoffs, narrow-minded management practices, outsourcing etc. have been held responsible for this trend which only promises to exacerbate in the near future. All eminently sensible points. But one thing should be clear; drug discovery remains hard because we still just don't understand a lot of the basic science very well. This is something that should always be on the mind of anyone who wants to hold  non-scientific factors responsible for drug failures. The fact is that there still remain very basic challenges that drug discoverers have to surmount. And by scientific challenges I am not talking about cutting edge, futuristic, overhyped strategies like gene therapy and nanotechnology that haven't yet borne fruit. I am talking about fundamental challenges here, problems that have been realized for years and yet not solved.

A review in this week's issue of Journal of Medicinal Chemistry has an account of something that greatly contributes to one of these challenges; getting compounds into cells. It's a basic problem in developing any drug. You may have a molecule that looks miraculous in the test tube but which utterly fails once you put it into a living organism. Many factors can contribute to this lack of translation but one of the most basic reasons is simply that the compound is not getting inside the cell. Recall that the cell membrane is expressly designed to keep things out, which is a good thing for evolution but a bad thing for drug designers. The membrane is composed of phospholipids with all kinds of proteins and other biomolecules embedded within it. Drugs can get across this membrane by simple passive diffusion, although in some cases they may be shuttled across by special helper proteins. In general any foreign substance will have to be hydrophobic enough to get past this membrane. But even otherwise it will have to satisfy some simple properties; it can't be too big and charged for instance. And it can't be too hydrophobic otherwise it won't dissolve in the aqueous medium surrounding the membrane in the first place.

But hydrophobicity is where your troubles only begin. Cells have an assortment of watchdog proteins whose purpose is to keep out unwanted substances. In the modern world, "unwanted substances" includes pretty much all drugs. The J. Med. Chem. review focuses on one of these watchdogs - very likely their king - which plagues drug designers all the time; the P-glycoprotein efflux multi-drug transporter (Pg). The fancy name only hides the fact that it's essentially a simple pump embedded within the membrane, designed to throw drugs out. It's the ultimate bouncer; even drugs that have the right mix of hydrophobic and hydrophilic character quake and rapidly exit when they encounter PgP. In fact the protein was discovered when it was found that some cancers were becoming resistant to certain drugs; what was happening was that these drugs were being pumped out or "effluxed". Even worse, the presence of these drugs was increasing the expression of the protein. Later it was found that a wide variety of drugs bind to and increase the expression of Pgp, reducing their effective concentration inside the cell; it's still one of the principal mechanisms of resistance in some kinds of cancer. 

Progress was only hindered by not knowing the structure of the protein (a part of which is illustrated above) which was only recently and partially solved by x-ray crystallography, and even then it's not really helping. The protein's structure and interior are exquisitely hideous to say the least; 12 transmembrane segments composed of 1280 amino acids, a mammoth internal cavity of 6000 Ã…3 and a wondrously complex mechanism of compound binding and extrusion during which the protein undergoes a massive conformational challenge. As it snakes its way through the lipid bilayer and wraps itself around drugs, the precision of this molecular machine would be wholly admirable if it were not for the eminent heartburn that it causes drug discoverers. 

The constant extrusion of drugs by Pgp means that you may have to increase the dosage of your drugs (or saturate the protein with another drug) to maintain high blood levels, but that's just skimming the surface of the Pgp world of pain. Since its original discovery the protein has turned into a minor nemesis for drug designers and it's become a part of a notorious list of proteins called "anti targets" that can lead to side-effects and lack of efficacy (we encountered one of these anti targets before - the hERG channel protein). And that's not only because Pgp is ubiquitously expressed in the intestine and liver where most drugs are metabolized. Nor is it because of its special role in the blood-brain barrier which creates additional problems for CNS drugs. It's because when it comes to Pgp, scientists may not have a clue about how to possibly solve the problem. Usually when you encounter an unwanted protein that binds to your drugs, you try to add a modification to your drug to block this binding. In many cases, structure-activity relationship (SAR) can help you pin down some trends; you remove a basic nitrogen atom here, you get rid of a double bond there, you add a fluorine to that ring. If you know what kinds of molecular features a rogue antitarget protein likes, you can avoid those features in your drug.

But not so for Pgp. Pgp is, in the words of the review author, a "hydrophobic vacuum cleaner". And it's one that will put Sir James to shame. What kinds of molecules does it like as substrates? Here's a description from Kerns and Di's book "Drug-like Properties":

"The substrate specificity for Pgp is very broad. Compounds ranging from a molecular weight of 250 to 1850 are known to be transported by Pgp. Substrates may be aromatic, non-aromatic, linear or circular. They can be basic, acidic, zwitterionic or uncharged. Some substrates are hydrophobic, others are hydrophilic and yet others are amphipathic."

The authors could have saved themselves all those words by simply saying something like "Pgp binds to and extrudes everything in the universe except possibly the human soul". As should be obvious, this kitchen sink description of every molecule of every kind is not exactly a guide for drug designers to rationally add modifications that would prevent Pgp binding. I was myself part of a project where the whole "rational" drug design process was going extremely well - well-defined changes in structure contributing to improved potency - until we found that the compounds were being generously ejected by Pgp. At this point our gung-ho approach screeched to a halt and we found ourselves transported from the sunlight of rational design into the night of Pgp-mediated chaos. Where before we had been confidently stepping across a brightly lit landscape, we now found ourselves groping around in the dark with our eyes closed. It was like falling down an abyss. There was no rational modification to our existing molecules that would ensure a Pgp-free existence. From then on it was largely about gut feelings, intuition and Hail Mary passes.

In reality, Pgp binding is sometimes considered so painfully complex to circumvent that the best strategy may actually be to wave a wand and temporarily forget about it. Counterintuitive as this seems, what this strategy means is that often the best way to prevent Pgp drug binding is to simply increase the passive diffusion of your compounds so much that it swamps any Pgp-enabled extrusion. Basically you just keep on bumping up the magnitude of one process until it can one-up the opposing process.

The present review in J. Med. Chem. provides some respite from this depressing existence. The author describes several case studies where strategies like tying up hydrogen bond donors, getting rid of them, reducing basicity or reducing polar surface area helped to design out Pgp binding. These are valuable examples, but they are anecdotal nonetheless and may not work for other molecules with similar functionalities. Well-defined rational approaches to Pgp binding are still lacking and the complex mechanism of the Pgp-drug binding precludes designing specific Pgp inhibitors even if the structure is known. Reviews like the present one provide useful guidelines, but for the foreseeable future at least, Pgp will stand in splendor as one among a handful of scientific challenges that continue to make drug discovery just so damn difficult.
Image source: Wikipedia

"Arsenic bacteria": If you hadn't nailed 'im to the perch 'e'd be pushing up the daisies

Rosie Redfield (who blogs on this network) has just published an official, careful and decisive rebuttal to the "arsenic bacteria" fiasco in collaboration with a group at Princeton. The paper which will appear in Science is under embargo for now, but there is a copy available at that bastion of free publication arXiv. Readers may remember Redfield as the scientist who offered the most meticulous preliminary criticism of the original paper by Felisa Wolfe-Simon and others. Wolfe-Simon and the rest of the arsenic group refused to engage in debate with Redfield and other critics at the time, citing the "non-official" nature of the offered criticism and asking for publication in a more formal venue. Looks like they finally got their wish.

The abstract could not be clearer:

"A strain of Halomonas bacteria, GFAJ-1, has been reported to be able to use arsenate as a nutrient when phosphate is limiting, and to specifically incorporate arsenic into its DNA in place of phosphorus. However, we have found that arsenate does not contribute to growth of GFAJ-1 when phosphate is limiting and that DNA purified from cells grown with limiting phosphate and abundant arsenate does not exhibit the spontaneous hydrolysis expected of arsenate ester bonds. Furthermore, mass spectrometry showed that this DNA contains only trace amounts of free arsenate and no detectable covalently bound arsenate."

It's a fairly short paper but there are many observations in it which quite directly contradict the earlier results. The strain of bacteria that was claimed to grow only when arsenic was added to the medium was found to not grow at all. In fact it did not budge even when some phosphate was added, growing only after the addition of other nutrients. Trace element analysis using several techniques detected no arsenate in DNA monomers and polymers. This is about as definitive an argument as can be published indicating that the claims about the bacteria using arsenic instead of phosphorus in their essential biomolecules were simply incorrect. Much credit goes to Redfield who patiently and probingly pursued the counterargument, undoubtedly at the expense of other research in her lab. In addition she did open-science a great service and described all the ongoing research on the blog. She sets a standard for how science should be done, and we should hope to see more of this in the future.

Sociologically the episode is a treasure trove of lessons on how science should not be done. It checks off some standard "don'ts" in the practice of science. Don't fall prey to wishful thinking and confirmation bias that tells you exactly what you wanted to hear for years. Don't carry out science by press conference and then refuse to engage in debate in public venues. And of course, don't fail in providing extraordinary evidence when making extraordinary claims. If the original paper had been published cautiously and without hullabaloo, it would have become part of the standard scientific tradition of argument and counterargument. As it turned out, the publicity accompanying the paper made it a prime candidate for demolition by blogs and websites. If nothing it provided a taste of how one needs to be extra careful in this age of instant online dissemination. There's also some "do's" that deserve to be mentioned. The researchers did reply to criticism later and make their bacterial strains available to everyone who wanted to study them in a gesture of cooperation, but their earlier behavior left a bad taste in everyone's mouth and detracted from these later acts.

When the original paper came out, many of us were left gaping with eyes wide open at visions of DNA, ATP, phosphorylated proteins and lipids swirling around in a soup of arsenic, carrying out the exact same crucial biological processes that they were carrying out before without skipping a heartbeat. We just had a gut feeling that this couldn't be quite right, mainly because of the sheer magnitude of the biochemical gymnastics an organism would have to undergo in order to retool for this drastically different environment. Gut feelings are often wrong in science, but in this case it seems they made perfect sense.

What next? As often happens in science, I suspect that the defenders of the original paper will not outright capitulate but will fight a rearguard retreat until the whole episode drops off everyone's radar. But this paper here, it clinches the case for normal biochemistry as well as anything could. Good old phosphorus is still one of life's essential elements, and arsenic is not.

An almost-Nobelist's lesson to his daughter

Last year's physics Nobel Prize was awarded to a group of three people who discovered one of the most significant recent facts about our universe; the fact that its expansion is accelerating. It turns out that two out of the three laureates had gotten their Ph.D. with Robert Kirshner at Harvard, who among other things has written the excellent book "The Extravagant Universe". Kirshner was involved in a big way with the supernova project that discovered the acceleration; he trained dozens of students apart from the two prize winners. He would almost certainly have won the prize had it not been restricted to three scientists. One might have expected him to feel at least a few pangs of regret about not winning. But even if he did, his response to his daughter which she published in this week's Science is worth reading:

One morning this past October, I woke up to find an email from my father. Reading the subject line, I immediately burst into tears. My father, Robert Kirshner, is an astronomy professor at Harvard University. The subject of his e-mail was, “My Students won the Nobel Prize!”...I was worried because I knew my father to be incredibly competitive...But as it turns out, his response to not winning is the lesson I really value. When I spoke to him that morning, he amazed me: He was proud of the people he has worked with and taught; he was generous-spirited; he was funny; and he had perspective. What a relief! It turns out that a guy who spent his life trying to understand the immensity of the universe could put into perspective the relative importance of which particular earthling took home the ribbons and the medals and got to bow to the King of Sweden. It turns out that what was really important to him was the work itself, the wonder of this extraordinary universe, the honor and the fun of trying to figure things out, and maybe, just a little bit, the thrill of the chase. I admire all the terrific scientists who contributed to this greater understanding of the universe we live in, but in particular I admire my father, whose expansive understanding of what really matters taught me something of astronomical importance.

That's a lesson which, while contrary to the common human emotions of jealousy and vanity, seems to be alive and well in scientists like Kirshner and it's worth always keeping in mind. Science is inherently a community enterprise; even the science done by supposed loners like Newton and Einstein would not have been possible had it not built on a body of work extending back several centuries. The culmination of this body of work is what's real. The prizes are incidental.

The protein makes the poison: Dancing fruit flies and terfenadine

"Chemophobia" is the name of the exasperating phenomenon in which every material substance is branded as a "chemical" and made to look dangerous irrespective of context. Since everything in the universe is supposedly material, by definition chemophobia extends to everything. The media in particular has eagerly latched on to this idea, forgetting that almost everything (not just chemicals but life, liberty and the pursuit of happiness) is dangerous in the wrong quantities and context and harmless in the right ones. 

Matt Hartings at Sciencegeist had the excellent idea for us bloggers to do our part in dispelling chemophobia. He wants us to write about our favorite toxic chemical compounds. This will not only give us an opportunity to explore the many incarnations of toxicity but will also help inform the public about the highly context-specific safety and toxicity of chemicals.

My fellow bloggers have done a great job so far in documenting the various facts and myths about toxic molecules (you can find summaries on Matt's blog). A resounding theme in their posts is that "the dose makes the poison". It's an idea which goes back to Paracelsus in the 15th century and sounds intuitively true (consider the widespread injunction against gluttony), but which seems surprisingly recalcitrant to being universally accepted. This dose-specific toxicity especially makes its appearance in medicine, with unfortunate reports of celebrities fatally overdosing on prescription drugs regularly appearing in the news media. Strangely, the same media which readily accepts the fact that prescription drugs are safe as long as they are not abused in large quantities abandons its critical attitude when talking about "chemicals" in our food and clothing.

Dose-specific toxicity is indeed of paramount importance in medicine, but if you delve deeper, the common mechanism underlying the toxicity of many drugs often has less to do with the specific drugs themselves and more to do with the other major player in the interaction of drugs with the human body - proteins. Unwarranted dosages of drugs are certainly dangerous, but even in these cases the effect is often mediated by specific proteins. Thus in this post, I want to take a slightly different tack and want to reinforce the idea that when it comes to drugs it's often wise to remember that "the protein makes the poison". I want to reinforce the fact that toxicity is often a function of multiple entities and not just one. In fact this concept underlies most of the side-effects of drugs, manifested in all those ominous sounding warnings delivered in rapid fire intonations in otherwise soothing drug commercials.

What do I mean by "the protein makes the poison"? Almost every drug demonstrates its effects by binding to specific proteins which may be involved in particular diseases, and the goal of pharmaceutical research is to find molecules that target and inhibit or activate these proteins. There is of course much more to a drug than just inhibition of a protein, but that's the fundamental challenge. This goal was delineated during the turn of the twentieth century in Paul Ehrlich's notion of a "magic bullet", a compound that would hit only the rogue protein and nothing else. We are still trying to implement Ehrlich's program and in the process have discovered how hideously complicated the process is.

The thing is, in spite of much progress we still understand woefully little about the human body. When we design a drug to inhibit one protein, it has to contend with the thousands of other proteins in the body which perform crucial functions. Making a drug that binds to a protein is essentially like designing a key to fit a lock. Even if you think you have a perfect key that fits only one lock, the number of locks with similar structures is so large that it's very likely for parts of the key to fit other locks. And if these other locks or proteins play fundamental roles in normal physiological processes, you may be in trouble. In fact there's a name for this group of unwanted proteins - antitargets - and there are entire books written on how to avoid them.

Ideally you have to contend with every other protein when your goal is to target only one, but somewhat fortunately, the history of drug research has found out a handful of key proteins which seem to be often hit, leading to side-effects. In this post I will focus on two, and I will illustrate both through the example of the drug terfenadine (illustrated on top). Interestingly, the story of terfenadine reinforces the idea about both dosage and protein-specific toxicity.

Terfenadine was introduced in 1985 as an anti-allergy drug. Things seemed to be going well for its maker Hoechst Marion Roussel until 1990 when troubling reports emerged of a serious and potentially lethal side effect. This side effect was a perturbation of the heart's rhythm. It can be of several types, all of which are usually lumped under the title of "arrhythmias". In particular, terfenadine caused two phenomena with the impressive names of QT prolongation and torsades de pointes.

The heart is a pump, but it's also a kind of electrical motor with its own electrical cycle. This cycle is governed by the influx and outflux of various ions into heart cells; most commonly, sodium, potassium, calcium and chloride. The cycle shows up as peaks and troughs in electrocardiograms (ECGs). Each peak is alphabetically labeled, and the interval between the trough Q and the peak T is particularly important. It turns out that several drugs including terfenadine prolong this interval, essentially throwing the heart's rhythm out of sync. It is not hard to see that the consequences of disturbing this very fundamental rhythm of life can be catastrophic; the heart can stall, go into cardiac arrest and kill the unfortunate victim. QT prolongation can also be part of a larger indication called torsades de pointes, characterized by a specific shape of the ECG.

But what's responsible for this effect at the molecular level is a unique protein called human ether a-go-ho (hERG). The protein is an ion channel conducting potassium ions through heart cells, thus its crucial significance in maintaining heart rhythm should not be surprising. Terfenadine and several other drugs (most notably some antidepressants and antipsychotics) bind to this protein with high affinity and can even block it. The amusing name of the protein points to an amusing origin. The protein was a product of the human analog of genes discovered in fruit flies by researchers at the University of Wisconsin who were studying mutations in these genes. They found that the mutant flies' legs started to shake when they were anesthetized, making the insects look like entomological versions of Elvis. Another scientist at the City of Hope remembered where he had seen humans doing a similar dance; at the Whisky a Go Go nightclub in West Hollywood. It was the ultimate in anthropomorphization. Here's what part of the protein looks like.

When the FDA found out about the dangerous side effects that terfenadine mediated through the hERG ion channel, they sent a letter to doctors who were prescribing the drug and issued a black box warning. In 1997 the FDA finally withdrew terfenadine; after all there were several anti-allergy medications out there and there was no need to market an especially dangerous one. Since then, testing potential drugs against hERG is a mandatory part of seeking FDA approval and there is much research dedicated to finding out specific molecular features of drugs which may turn out to be hERG blockers; one common determinant seems to be the presence of a positively charged basic nitrogen atom. There are entire lists of drugs including marketed ones that can cause QT problems to varying extents under different conditions.

So there it is, toxicity mediated not just by a particular "chemical" but by its interaction with a particular protein. But the story does not end there. Toxicity problems with terfenadine seemed to occur - you guessed it - only at high dosages. The dose indeed made the poison. But there was an added twist. Some patients experienced hERG blockage only when they were taking other drugs, most notably the antibiotic erythromycin. Surprisingly this also happened when they were drinking quantities of, of all things, grapefruit juice. Grapefruit juice has also turned out to be important in the effects of other popular drugs like statins for heart disease.

What was going on? When terfenadine is administered, like any foreign molecule it has to first get through the gut wall and the liver to enter the bloodstream. And it's in the liver that it encounters a protein called cytochrome P450. This crucial protein is the great gatekeeper of the human body, denying entry to thousands of molecules which it deems to be poisonous. It is responsible for the metabolism of about 75% of all drugs. It served a necessary function during evolution when organisms had to keep potentially poisonous chemicals out, but it haunts drug discovery scientists in their dreams because of its ability to affect drug structures in unexpected ways. The centerpiece of P450 is an iron atom that oxidizes electron-rich bonds in molecules. Most of the times the protein induces an oxidation reaction in a drug that changes it to something else. As a further testament to the complexities of drug development, that "something else" itself can be toxic, beneficial or neutral. In case of terfenadine there was a stroke of good luck; cytochrome P450 was transforming the compound into another drug called fexofenadine. Chemists will recognize the small difference in the structures - a single carboxylate group at the terminal end. 


But as is often the case in the wonderful world of pharmacology, this tiny difference had momentous consequences; fexofenadine no longer bound to hERG with high affinity to cause QT-prolongation. What happened at high doses was that terfenadine saturated cytochrome P450 and some of it made its way into the bloodstream without being transformed into fexofenadine. Similarly the compounds in grapefruit juice preferentially bound to cytochrome P450, again allowing terfenadine to get past the protein. And this terfenadine which escaped the clutches of cytochrome P450 blocked hERG. One thing is clear here; it is chilling to contemplate the effects of terfenadine had it not been metabolized to fexofenadine by P450 in the first place.

This fascinating (at least for me) story of terfenadine drives home many important points regarding toxicity. Firstly, it takes two to tango, and toxicity is always a function of a drug and its target and not just of the drug alone. Secondly, we again had a case where "the dose made the poison". And thirdly, the reason this was true was because of a guardian angel, a protein which changed terfenadine into something else that was not toxic; a corollary of this point is that it takes a tiny change to turn a toxic compound into a non-toxic one.

There should be little more evidence needed to prove that toxicity is a many splendored, context-specific thing.

All images are from Wikipedia